Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan
November 06 2020 - 8:00AM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing antiviral therapeutics to improve
the lives of patients suffering from life-threatening viral
infections, today announced the appointment of Barbara Duncan to
its Board of Directors, where she will also serve as Chair of the
Audit Committee.
“We are delighted to welcome Barbara to the Atea Board of
Directors. Her financial acumen combined with her considerable
experience advising a variety of biopharmaceutical companies will
make Barbara’s guidance invaluable to Atea as we navigate the
public markets and advance our antiviral pipeline,” said
Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder
of Atea Pharmaceuticals.
"I am proud to join Atea at this critical juncture as the
Company recently transitioned to a publicly traded entity," said
Ms. Duncan. "Importantly, I am excited to be a part of the team
working to make a difference in this global pandemic through the
advancement of AT-527, an oral product candidate for the treatment
of patients suffering from COVID-19.”
Ms. Duncan previously served as Chief Financial Officer and
Treasurer at Intercept Pharmaceuticals. Prior to her leadership
role with Intercept, Ms. Duncan was Chief Financial Officer and
then Chief Executive Officer at DOV Pharmaceutical, which was sold
to Euthymics Bioscience. Before that, she served as Vice President
of Corporate Finance - Global Healthcare at Lehman Brothers and as
Director of Corporate Finance at SBC Warburg Dillon Read. Ms.
Duncan currently serves on the Board of Directors of Adaptimmune
Therapeutics, Fusion Pharmaceuticals, Jounce Therapeutics, ObsEva
SA, and OVID Therapeutics.
Ms. Duncan received an M.B.A. from the Wharton School,
University of Pennsylvania and a B.S. from Louisiana State
University.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical stage biopharmaceutical
company focused on discovering, developing and commercializing
therapies to address the unmet medical needs of patients with
life-threatening viral diseases. Leveraging the Company’s deep
understanding of antiviral drug development, nucleoside biology,
and medicinal chemistry, Atea has built a proprietary purine
nucleotide prodrug platform to develop novel product candidates to
treat single stranded ribonucleic acid, or ssRNA, viruses, which
are a prevalent cause of severe viral diseases. Currently, Atea is
focused on the development of orally available, potent, and
selective nucleotide prodrugs for difficult-to-treat,
life-threatening viral infections, including severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that
causes COVID-19, hepatitis C virus (HCV) infection, dengue virus,
and respiratory syncytial virus (RSV). For more information, please
visit www.ateapharma.com.
Contacts
Investors:Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Media:Carol Guaccero301-606-4722contactus@ateapharma.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Apr 2023 to Apr 2024